News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Launches ChoiceDM(TM) A1C Home Test -- First At-Home Test To Measure Long Term Blood Sugar Control


10/19/2005 5:12:22 PM

NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company , today announced the availability of the ChoiceDM(TM) A1C Home Test, the only over-the-counter test to measure glycated hemoglobin (HbA1c or A1C) and provide immediate results at home. The pager-sized disposable device allows diabetes patients to obtain A1C results at home to track their progress and to assist their healthcare professionals in monitoring response to treatment. The ChoiceDM A1C Home Testis now available in pharmacies without prescription.

The American Diabetes Association (ADA) has identified A1C as the preferred standard indicator for measuring long-term blood sugar control. The ADA recommends A1C testing to be performed on all patients with diabetes up to four times a year. Patients modifying their diet or exercise regimen may also measure A1C levels to track their progress. Previously, most A1C testing was performed in a doctor's office or laboratory setting. FDA-cleared, CLIA- waived and NGSP-certified, the three-step test accurately provides A1C results in eight minutes from a small drop of blood.

"As a leader in diabetes management, Bristol-Myers Squibb is pleased to offer patients this important test that can be used in the comfort and convenience of their own home," said Gary Matthews, President, Worldwide Consumer Medicines, Bristol-Myers Squibb. "The addition of the A1C home test to our innovative ChoiceDM franchise demonstrates our ongoing commitment to providing important new options that may benefit people living with diabetes."

"The availability of the ChoiceDM A1C Home Test is important news for the more than 18 million Americans living with diabetes," said Dr. Steve Edelman, who has lived with diabetes for over 30 years, and Professor of Medicine at the University of California, San Diego and Director of Taking Control of Your Diabetes (501c3). "Not only is it more convenient, but it will also motivate patients to be more informed and active participants in their own diabetes management. There is no question that the widespread availability of the ChoiceDM A1C Home Test will improve diabetes care over the short and long term."

About A1C

Unlike daily glucose monitoring that is subject to fluctuations throughout the day, A1C (also known as glycosylated hemoglobin) is a measure of the body's average glucose level over a period of two-to-three months. According to the ADA, A1C is the preferred standard for assessing a diabetes patient's overall glycemic control. Studies have shown that a one percent reduction in A1C lowers the risk of serious complications, such as eye, kidney and nerve damage, by 37 percent. Reduction in A1C also decreases the risk of other serious complications associated with diabetes including stroke, heart disease, and amputation or death from peripheral arterial disease. The ADA recommends that patients with diabetes maintain an A1C level of seven percent or less in order to reduce their risk of these complications. However, less than half of Americans with diabetes are estimated to have achieved this goal.

About the CHOICEDM A1C Home Test

ChoiceDM A1C Home Test is the only over-the-counter, quantitative test available for consumer use to measure glycated hemoglobin (HbA1c or A1C) and provide immediate results at home. The pager-sized ChoiceDM A1C Home Test is a single-use, disposable device that allows diabetes patients to obtain A1C results at home to track their progress and to assist their healthcare professionals in monitoring response to treatment.

ChoiceDM A1C Home Test allows point-of-care access to A1C results without the high-cost and complexity of instrument-based systems. FDA-cleared, CLIA- waived and NGSP-certified, the three-step test accurately provides A1C results in eight minutes from a small drop of blood.

About ChoiceDM(TM)

The ChoiceDM line of consumer products includes nutritional products such as sugar-free shakes and nutrition bars. All twelve bars and drinks contain slow-absorbing carbohydrates to help manage blood sugar as part of a healthy diet. In addition, ChoiceDM offers foot and skin care products like friction- reducing socks and moisturizing creams. For more information on ChoiceDM, visit http://www.choicedm.com/.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. For more information, visit http://www.bms.com/.

Under an agreement with Metrika, Inc. of Sunnyvale, Calif., Bristol-Myers Squibb has exclusive consumer sales and distribution rights in the United States to the A1C home test diabetes monitor. Bristol-Myers Squibb markets the device under the company's ChoiceDM(TM) line of nutrition, foot and skin care products.

Contacts: Elyse Margolis Rob Hutchinson Ogilvy Public Relations Bristol-Myers Squibb 212-880-5329 609-252-3901 elyse.margolis@ogilvypr.comrobert.hutchinson@bms.com

Bristol-Myers Squibb

CONTACT: Elyse Margolis of Ogilvy Public Relations, +1-212-880-5329,elyse.margolis@ogilvypr.com; or Rob Hutchinson of Bristol-Myers Squibb,+1-609-252-3901, robert.hutchinson@bms.com


Read at BioSpace.com

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES